Immunotherapy plus chemo takes on tough breast cancer
NCT ID NCT06318897
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy (carboplatin and paclitaxel) can improve outcomes for people with stage 1 triple-negative breast cancer. The study will enroll 28 participants at MD Anderson Cancer Center and will monitor safety and side effects. Triple-negative breast cancer is an aggressive type that lacks common treatment targets, so new approaches are needed.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pembrolizumab (Keytruda) plus carboplatin and paclitaxel chemotherapy
- What this could lead to
- If successful, this could offer a more effective treatment option for early-stage triple-negative breast cancer, potentially reducing the risk of recurrence.
- What could go wrong
- This is a small, early-phase study with only 28 participants, so results may not apply to all patients. The combination may cause significant side effects, and it's not yet known if it works better than standard treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE 1 CT1B-T1CN0M0 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a High-Fiber diet shield the gut during breast cancer therapy?
- Can mapping tumor DNA unlock personalized breast cancer care?
- Can a Two-Pronged antibody boost Chemo's power against a tough breast cancer?
- Can a new drug rally the immune system against Hard-to-Treat cancers?
- Could an oral chemo pill improve breast cancer treatment?
- Can a new nucleotide analogue boost cancer treatment?